Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Receivables - AccuredRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fulcrum Therapeutics (FULC) Total Non-Current Liabilities (2019 - 2026)

Fulcrum Therapeutics (FULC) has disclosed Total Non-Current Liabilities for 7 consecutive years, with $17.1 million as the latest value for Q4 2025.

  • Quarterly Total Non-Current Liabilities fell 2.29% to $17.1 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $17.1 million through Dec 2025, down 2.29% year-over-year, with the annual reading at $17.1 million for FY2025, 2.29% down from the prior year.
  • Total Non-Current Liabilities for Q4 2025 was $17.1 million at Fulcrum Therapeutics, up from $16.3 million in the prior quarter.
  • The five-year high for Total Non-Current Liabilities was $34.3 million in Q2 2022, with the low at $14.0 million in Q1 2025.
  • Average Total Non-Current Liabilities over 5 years is $21.6 million, with a median of $21.9 million recorded in 2023.
  • The sharpest move saw Total Non-Current Liabilities rose 17.41% in 2022, then fell 29.63% in 2025.
  • Over 5 years, Total Non-Current Liabilities stood at $23.5 million in 2021, then grew by 17.41% to $27.5 million in 2022, then fell by 19.03% to $22.3 million in 2023, then fell by 21.6% to $17.5 million in 2024, then decreased by 2.29% to $17.1 million in 2025.
  • According to Business Quant data, Total Non-Current Liabilities over the past three periods came in at $17.1 million, $16.3 million, and $14.3 million for Q4 2025, Q3 2025, and Q2 2025 respectively.